JP2021522161A5 - - Google Patents

Info

Publication number
JP2021522161A5
JP2021522161A5 JP2020556835A JP2020556835A JP2021522161A5 JP 2021522161 A5 JP2021522161 A5 JP 2021522161A5 JP 2020556835 A JP2020556835 A JP 2020556835A JP 2020556835 A JP2020556835 A JP 2020556835A JP 2021522161 A5 JP2021522161 A5 JP 2021522161A5
Authority
JP
Japan
Prior art keywords
dry powder
inhalable dry
itraconazole
inhalable
liquid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020556835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522161A (ja
JP7549534B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028089 external-priority patent/WO2019204583A1/en
Publication of JP2021522161A publication Critical patent/JP2021522161A/ja
Publication of JP2021522161A5 publication Critical patent/JP2021522161A5/ja
Application granted granted Critical
Publication of JP7549534B2 publication Critical patent/JP7549534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020556835A 2018-04-18 2019-04-18 イトラコナゾールを含む肺内投与のための抗真菌配合物 Active JP7549534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659479P 2018-04-18 2018-04-18
US62/659,479 2018-04-18
PCT/US2019/028089 WO2019204583A1 (en) 2018-04-18 2019-04-18 Antifungal formulations for pulmonary administration comprising itraconazole

Publications (3)

Publication Number Publication Date
JP2021522161A JP2021522161A (ja) 2021-08-30
JP2021522161A5 true JP2021522161A5 (enExample) 2022-04-14
JP7549534B2 JP7549534B2 (ja) 2024-09-11

Family

ID=66429608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020556835A Active JP7549534B2 (ja) 2018-04-18 2019-04-18 イトラコナゾールを含む肺内投与のための抗真菌配合物

Country Status (4)

Country Link
US (1) US20210145739A1 (enExample)
EP (1) EP3781125A1 (enExample)
JP (1) JP7549534B2 (enExample)
WO (1) WO2019204583A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658610B (zh) * 2020-07-31 2022-05-24 上海方予健康医药科技有限公司 一种供雾化器用的三氮唑类抗真菌药物的混悬液
IT202000030443A1 (it) * 2020-12-10 2022-06-10 Zambon Spa Polvere inalabile comprendente voriconazolo in forma cristallina
IT202000030437A1 (it) * 2020-12-10 2022-06-10 Zambon Spa Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
JP2025529125A (ja) 2022-08-31 2025-09-04 パルマトリックス オペレーティング カンパニー，インコーポレイテッド イトラコナゾール乾燥粉末を使用する方法
CN117323300A (zh) * 2023-11-03 2024-01-02 苏州大学 可经口吸入的伊曲康唑纳米晶聚集体微粒及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
KR100743404B1 (ko) * 2000-12-21 2007-07-30 넥타르 테라퓨틱스 폴리엔 항균제의 폐 전달
AU2003276131A1 (en) * 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
WO2006026502A1 (en) * 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
US20110142914A1 (en) * 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
EP2095816A1 (en) 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety
AU2011320159B2 (en) * 2010-10-29 2016-12-22 Western University Of Health Sciences Ternary mixture formulations
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
IL265913B2 (en) * 2016-10-14 2024-07-01 Pulmatrix Operating Co Inc Respirable Dry Powder Comprising Itraconazole In Crystalline Form And Its Use For Manufacturing A Medicament For Treating Fungal Infection

Similar Documents

Publication Publication Date Title
JP2021522161A5 (enExample)
JP2019534270A5 (enExample)
AU2018222983B2 (en) Ultra Low Density Pulmonary Powders
RU2013118453A (ru) Катионы одновалентных металлов сухих порошков для ингаляций
JP7623854B2 (ja) 乾燥粉末配合および使用方法
CN103841960B (zh) 用于吸入的方法和制剂
RU2766086C2 (ru) Противогрибковые сухие порошки
CN102946868B (zh) 包含抗毒蕈碱药的干粉制剂
JP2013540123A5 (enExample)
JP2024113096A5 (enExample)
CN103052379A (zh) 包含磷酸二酯酶抑制剂的干粉制剂
WO2011121425A1 (en) Pharmaceutical powder composition for inhalation
JP2022513566A5 (enExample)
JP7592582B2 (ja) 真菌感染症の治療に使用するための呼吸可能な乾燥粉末製剤
JP2017523189A (ja) 吸入用の乾燥粉末製剤
CN110582269A (zh) 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
JP2023521396A (ja) ペラミビル乾燥粉末吸入剤及びその調製方法
JP2017530988A5 (enExample)
JP2024541985A (ja) 肺高血圧症を治療するための方法および組成物
WO2022023456A1 (en) Pharmaceutical compositions comprising nano embedded microparticles and methods of use
RU2820457C2 (ru) Способы лечения грибковых инфекций
KR102259824B1 (ko) 보센탄을 함유한 약학 제제
Moon et al. and Robert O. Williams III1
Das¹ et al. Anti-Tubercular Drugs
KR20180052566A (ko) 폐 전달용 트립탄 분말